Keywords: Takeda, Vedolizumab, Ph III, Crohn's disease

Takeda's vedolizumab meets primary endpoints in Ph III Crohn's disease study

Article | 13 May 2012

Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) has reported positive top-line results from the international, randomized, placebo-controlled, double-blind GEMINI ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Takeda Pharmaceuticals

Go to company listing

Related Drugs

vedolizumab

Go to drug listing